Drug Discovery

A 2000-participant study in Europe has examined how drugs – and combinations of drugs – can affect the microbiota in our gut.

What can the Professor X of Heidelberg tell us about a new way of tackling cancer?

Antimicrobial resistance is an ongoing challenge for the pharmaceutical industry. What solutions can be created to address the problem?

Allergies pose a significant challenge to patients worldwide. How can we use novel immunotherapy approaches to lessen their therapeutic burden?

Can newly discovered antibodies help us do away with annual flu vaccinations?

An interview with Ken Gruber of Endevica Bio on his work producing a treatment for cachexia, a wasting condition common in late-stage cancer.

A partnership between Gilead Sciences and Georgia State University has tested a new oral antiviral for COVID-19.

To optimize drug development, the opinions of all stakeholders – including patients – must be heard.

Two members of the Drugs for Neglected Diseases initiative lay out how they improved access to Hep C treatment in Southeast Asia and beyond.

Exploring the potential of vaccines for treatment equity.